F5 (coagulation factor V; HGNC:3542, NCBI Gene 2153) is the gene on chromosome 1q24.2 encoding factor V — the procofactor that thrombin activates to FVa, the cofactor of the prothrombinase complex that generates the thrombin burst of coagulation. Its Arg506Gln substitution (Factor V Leiden) removes one of activated protein C's cleavage sites: the most common inherited thrombophilia in Europeans.
Approved Symbol
F5 (HGNC:3542)
Chromosomal Locus
1q24.2
Encoded Product
Factor V — a 330-kDa procofactor (2,224 aa) of the coagulation cascade
Factor V Leiden: APC resistance and venous-thrombophilia risk stratification
Gene Structure & Expression
Genomic organization: 25 exons; the exon-10 G1691A (R506Q) Leiden mutation — heterozygote frequency ~3–8% in European populations, essentially absent in most others — the founder-mutation geography of thrombophilia genetics.
Expression: Hepatocytes (the plasma pool) and megakaryocytes (the platelet α-granule pool, ~20% of total factor V) — the two sources converging in the hemostatic plug, see the fibrinogen page's cascade anatomy.
Molecular Function & Pathways
Procofactor activation: Thrombin and Xa cleave FV at Arg709/1018/1545 to FVa — the cofactor that accelerates prothrombin activation ~10,000-fold with Xa on phospholipid surfaces; the amplification loop's heart.
APC resistance mechanism: Activated protein C (with protein S) normally cleaves FVa at Arg306/506/679; the Leiden 506 loss slows inactivation ~10-fold — the hypercoagulable state's clean molecular explanation.
Clinical & Therapeutic Significance
Thrombophilia genetics: Heterozygous Leiden: ~3–8-fold venous-thrombosis risk (most carriers never thrombose); homozygous: ~50–80-fold; testing in unprovoked or recurrent VTE and before oestrogen therapy in familial contexts.
Management: Risk-stratified anticoagulation (provoked VTE with transient risk often not long-term anticoagulated); combined with prothrombin-gene or other defects compounding risk in family screening.